Brain Foundation Models for Neurological Health Prediction

Abstract

Brain foundation models represent a transformative advancement in the prediction and management of neurological disorders. These models, leveraging large-scale neuroimaging data and machine learning methodologies, offer unprecedented potential for early detection, risk stratification, and personalized therapy planning for a wide spectrum of neurological diseases. Recent studies highlight their promise in enhancing diagnostic accuracy, uncovering subclinical manifestations, and improving prognostic assessments. This review critically examines the current landscape of brain foundation models, focusing on their epidemiological impact, mechanistic underpinnings, clinical implications, and future directions for optimized neurological health prediction in clinical practice.

Introduction

Neurological disorders, encompassing conditions such as stroke, epilepsy, neurodegenerative diseases, and demyelinating syndromes, constitute a significant global health burden. The traditional approach to neurological diagnosis and risk prediction relies on a combination of clinical acumen, neuroimaging, and laboratory investigations. However, the growing complexity and heterogeneity of neurological diseases necessitate more sophisticated predictive tools. Brain foundation models, employing artificial intelligence (AI) and deep learning architectures, have emerged as cutting-edge instruments for translating multidimensional neuroimaging and clinical data into actionable insights for clinicians. This article offers a comprehensive review of these models, elucidating their epidemiological significance, pathophysiological rationale, risk assessment capabilities, clinical features discernment, diagnostic utility, and therapeutic implications.

Epidemiology / Disease Burden

Neurological disorders are a leading cause of disability-adjusted life years (DALYs) and mortality worldwide. According to the Global Burden of Disease Study 2019, neurological conditions account for over 16.5% of total global deaths, with stroke and Alzheimer’s disease being predominant contributors. Early detection and risk stratification are critical to mitigating this burden. Brain foundation models, trained on extensive population datasets, have demonstrated efficacy in identifying at-risk individuals prior to clinical manifestation, thus offering a scalable approach to population-level screening and intervention planning.

Pathophysiology

The underlying pathophysiology of neurological disorders often involves complex, multifactorial processes including neurodegeneration, demyelination, vascular compromise, and aberrant neural connectivity. Brain foundation models are designed to capture these pathophysiological signatures by extracting high-dimensional features from multimodal data such as structural and functional MRI, PET scans, and electroencephalography (EEG). These models can discern subtle morphological changes, connectivity disruptions, and metabolic alterations that precede overt clinical symptoms, thereby providing mechanistic insights into disease progression and facilitating hypothesis generation for future research.

Risk Factors

Major risk factors for neurological disorders include age, genetics, cardiovascular comorbidities, metabolic syndrome, environmental exposures, and lifestyle factors such as smoking and physical inactivity. Brain foundation models integrate these variables with imaging biomarkers, enabling nuanced risk stratification and personalized risk prediction. For example, AI-driven algorithms have identified unique imaging phenotypes associated with APOE4 genotype in Alzheimer’s disease, or microinfarct signatures predictive of vascular cognitive impairment, demonstrating their capacity for individualized risk profiling.

Clinical Features

Clinical features of neurological diseases range from cognitive impairment and motor deficits to sensory disturbances and behavioral changes. Foundation models aid clinicians by mapping these phenotypes to underlying neurobiological substrates. For instance, deep learning models have successfully correlated subtle changes in white matter integrity with early cognitive decline or motor dysfunction, thereby facilitating pre-symptomatic identification and timely referral for intervention. Additionally, these models can differentiate between overlapping clinical syndromes, such as distinguishing early Parkinson’s disease from atypical parkinsonian disorders, which is crucial for optimal management.

Diagnosis

Diagnostic precision is paramount in neurology, where early intervention can alter disease trajectories. Brain foundation models enhance diagnostic workflows by automating image analysis, quantifying lesion burden, and flagging abnormalities that may escape human detection. In multiple sclerosis, for example, AI models can detect new or enlarging lesions with high sensitivity, aiding in disease monitoring and therapy adjustment. Furthermore, these models are being validated for integration with clinical decision support systems, streamlining the diagnostic process and reducing interobserver variability.

Treatment & Management

While foundation models are not therapeutic entities, their predictive outputs inform clinical decision-making regarding treatment initiation, escalation, or de-escalation. Model-driven risk stratification guides the selection of disease-modifying therapies, timing of interventions, and monitoring strategies. For instance, in epilepsy, models predicting likelihood of drug-resistance can prompt early consideration for surgical evaluation. Moreover, these models facilitate shared decision-making by providing patients with individualized prognostic information, thereby aligning management plans with patient preferences and goals of care.

Recent Advances / Emerging Therapies

Recent advances in brain foundation models include the integration of multi-omics data (genomics, proteomics, metabolomics) with imaging and clinical variables, further refining disease prediction and subtype classification. Federated learning approaches enable collaborative model training across institutions while preserving data privacy, expanding the generalizability of predictive tools. Emerging therapies, such as targeted neurostimulation or disease-modifying agents, may benefit from model-guided patient selection to optimize therapeutic efficacy and minimize adverse effects. Ongoing research focuses on explainable AI to enhance clinician trust and regulatory acceptance.

Guideline Recommendations

Current clinical guidelines increasingly acknowledge the potential utility of AI-driven models in neurology. The American Academy of Neurology and the European Academy of Neurology recommend the cautious adoption of validated AI tools as adjuncts to, rather than replacements for, clinical judgment. Guidelines emphasize the need for robust external validation, transparency in model development, and consideration of ethical implications, including bias mitigation and patient data security. Continued professional education is essential to foster responsible integration of these models into routine care.

Conclusion

Brain foundation models signify a paradigm shift in neurological health prediction, offering the potential for earlier diagnosis, more accurate risk stratification, and personalized management strategies. As these models continue to evolve, multidisciplinary collaboration, rigorous validation, and adherence to ethical standards will be vital to their successful clinical translation. Ultimately, the integration of foundation models into neurological practice promises to enhance patient outcomes, reduce disease burden, and transform the future landscape of clinical neuroscience.